LUNG CANCER

FDA clears US enrollment for ateganosine plus cemiplimab in third-line NSCLC, testing telomere-targeting therapy after checkpoint and chemo failure.

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal trials.

Learn how TMB, PD-L1, smoking, and tumor burden shape first-line lung cancer immunotherapy choices, including when to add chemo or CTLA-4.

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

"Adjuvant selpercatinib should be considered as a new standard of care in early-stage RET fusion–positive lung cancer,” said Jonathan Goldman, MD.

Phase 3 NEOTORCH shows perioperative toripalimab plus platinum chemo boosts event-free survival and responses in resectable stage II–III NSCLC.

FDA grants priority review to neladalkib for post-TKI ALK+ NSCLC, aiming to beat resistance and brain metastases; decision due Nov 27, 2026.

Hafnium oxide nanoparticle radioenhancer adds safely to standard chemoradiotherapy in unresectable stage III NSCLC, showing deep responses and promising early efficacy.

FDA clears HARMONIC trial changes as LP-300 targets EGFR L858R lung cancer after TKI failure, aiming for longer dosing and lower toxicity.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

During a live Case-Based Roundtable event, Neal Ready, MD, dicussed the rationale for adding an anti–CTLA-4 agent to an anti–PD-1/PD-L1 backbone in NSCLC.

Explore how taletrectinib's CNS penetration may delay brain metastases and reduce the need for radiation in non–small cell lung cancer patients with ROS1.

FDA fast-tracks sevabertinib for first-line HER2-mutant metastatic NSCLC, spotlighting strong SOHO-01 responses and manageable safety.

Helena Yu, MD, discusses unmet needs and new frontiers in lung cancer treatment.

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.

Clinicians discuss using KEAP1/STK11 mutations to guide CTLA-4 therapy escalation in NSCLC, aiming to overcome PD-1 resistance and improve 5-year survival goals.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

FDA accepted the NDA for zipalertinib to treat previously treated metastatic NSCLC with EGFR exon 20 insertion mutations. Target action date: 2/27/27.

NCCN now recommends taletrectinib for ROS1+ NSCLC with brain metastases, citing high intracranial response rates in TKI-naive and pretreated patient cohorts.

Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists.

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ALK-positive NSCLC.

The ASTEROID trial shows adding durvalumab to SBRT significantly cuts tumor progression in early-stage NSCLC, though OS and DFS benefits remain uncertain.

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more precise, tailored therapy plan.

FDA fast tracks TRI-611, an ALK molecular glue degrader for refractory ALK+ NSCLC. Phase 1/2 trial targets resistance after 2 or more TKIs.

The proposed biosimilar demonstrated clinical equivalence to the reference product in overall response rate at 18 weeks, with a comparable safety profile, supporting regulatory submissions.